Abstract
EC: “the applicant shall not be required to provide the results of pharmacological and toxicological tests or the results of clinical trials if he can demonstrate: (i) either that the proprietary medicinal product is essentially similar to a product authorized … and that the person responsible for the marketing of the original product has consented to the … references contained in the file being used … (ii) or by detailed references to published scientific literature … (iii) or that the product is essentially similar to a product which has been authorized within the Community … for not less than 6 (10) years and is marketed in the Member State for which the application is made …; … where the … product is intended for a different therapeutic use from that of the other products marketed or is to be administered by different routes or doses, the results of appropriate pharmacological and toxicological tests and/ or clinical trials must be provided”; → see also hybrid procedure.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag/Wien
About this chapter
Cite this chapter
Nahler, G. (2009). abriged application. In: Dictionary of Pharmaceutical Medicine. Springer, Vienna. https://doi.org/10.1007/978-3-211-89836-9_3
Download citation
DOI: https://doi.org/10.1007/978-3-211-89836-9_3
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-89835-2
Online ISBN: 978-3-211-89836-9
eBook Packages: MedicineMedicine (R0)